CSL signs US$355 million deal with Alentis
- CSL partners with Alentis to co-develop lixudebart for rare kidney and liver diseases.
- CSL pays US$355 million upfront with up to US$1.2 billion in commercial milestones.
- The transaction aims to expand CSL's global nephrology franchise and rare disease pipeline.
CSL (ASX:CSL) signed an agreement with Alentis Therapeutics to co-develop and co-promote lixudebart in an upfront deal worth US$355 million.
The agreement expands the company's research pipeline beyond its traditional plasma therapies into targeted treatments for rare chronic conditions.
"We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease," said CSL Executive Vice President, Head of R&D Dr Bill Mezzanotte.
Under the terms, Alentis remains eligible for up to US$1.2 billion in additional milestone payments, while CSL will fully fund ongoing Phase 2 trials and planned Phase 3 trials.
The agreement positions CSL to split future global commercial profits on a 55% to 45% basis with Alentis.
Following the announcement, CSL’s share price came to $175.35.
The business continues to pursue external partnerships to strengthen its long-term renal care market presence.
This collaborative structure allows the enterprise to share developmental risk while securing majority economic rights in rare disease indications.
